Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database
Loading...
Date
Authors
Cortegiani, Andrea
Madotto, Fabiana
Gregoretti, Cesare
Bellani, Giacomo
Laffey, John
Pham, Tai
Van Haren, Frank
Giarratano, Antonino
Antonelli, Massimo
Pesenti, Antonio
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
Abstract
Background: The aim of this study was to describe data on epidemiology, ventilatory management, and outcome
of acute respiratory distress syndrome (ARDS) in immunocompromised patients.
Methods: We performed a post hoc analysis on the cohort of immunocompromised patients enrolled in the Large
Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study.
The LUNG SAFE study was an international, prospective study including hypoxemic patients in 459 ICUs from 50
countries across 5 continents.
Results: Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised, 38.9% of whom had an unspecified
cause. Pneumonia, nonpulmonary sepsis, and noncardiogenic shock were their most common risk factors for ARDS.
Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%;
p < 0.0001), despite similar severity of ARDS. Decisions regarding limiting life-sustaining measures were significantly
more frequent in immunocompromised patients (27.1% vs 18.6%; p < 0.0001). Use of noninvasive ventilation (NIV) as
first-line treatment was higher in immunocompromised patients (20.9% vs 15.9%; p = 0.0048), and immunodeficiency
remained independently associated with the use of NIV after adjustment for confounders. Forty-eight percent of the
patients treated with NIV were intubated, and their mortality was not different from that of the patients invasively
ventilated ab initio.
Conclusions: Immunosuppression is frequent in patients with ARDS, and infections are the main risk factors for ARDS
in these immunocompromised patients. Their management differs from that of immunocompetent patients,
particularly the greater use of NIV as first-line ventilation strategy. Compared with immunocompetent subjects, they
have higher mortality regardless of ARDS severity as well as a higher frequency of limitation of life-sustaining measures.
Nonetheless, nearly half of these patients survive to hospital discharge.
Description
Citation
Collections
Source
Critical Care
Type
Book Title
Entity type
Access Statement
Open Access
License Rights
Creative Commons Attribution 4.0 International License